|
|
|
SomantiX
SomantiX BV is a Dutch biotech
company focusing on the development of agents for imaging and therapy of cancer
through targeting of tumor blood vessels. Tumor growth beyond a certain
size requires new blood vessels
(angiogenesis) to assure continued delivery of oxygen and nutrients.
Anti-angiogenesis for cancer
SomantiX develops compounds
which specifically target these tumor blood vessels, resulting in starvation of cancer cells.
These agents are directed against a number of highly specific, proprietary targets of angiogenic endothelial cells.
|
|
November 7th, 2011 - Somantix
and VUMC receive EuroTransBio grant
August 10th, 2011 -
Job
openings
July 7th, 2011 - SomantiX
announces installment of its
Scientific Advisory Board
|
